Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Orthop. May 18, 2026; 17(5): 116525
Published online May 18, 2026. doi: 10.5312/wjo.v17.i5.116525
Published online May 18, 2026. doi: 10.5312/wjo.v17.i5.116525
Prognostic factors for patients undergoing surgery for femur metastases following systemic treatment
Yuki Ishibashi, Keiu Nakazato, Naohiro Tachibana, Jim Yu, Satomi Ugawa, Yuki Asanuma, Yusuke Kusunoki, Sho Hasebe, Tomoshi Takahashi, Nobuhiro Hara, Department of Orthopaedic Surgery, Japanese Red Cross Musashino Hospital, Musashino 180-0023, Tokyo, Japan
Author contributions: Ishibashi Y wrote the manuscript and reviewed the relevant literature; Nakazato K, Tachibana N, Yu J, Ugawa S, Asanuma Y, Kusunoki Y, Hasebe S, Takahashi T, and Hara N contributed to the conception and design of the study, and critically revised the manuscript. All the authors have read and approved the final manuscript.
Institutional review board statement: This study was approved by the institutional review board of our hospital (approval No. 7027). All study procedures were performed in accordance with the ethical standards of the Helsinki Declaration of 1975 (as revised in 2000) and national law.
Informed consent statement: Our consent is opt-out and there is no individual consent form.
Conflict-of-interest statement: The authors declare no conflicts of interest.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: Data sharing is not applicable to this article as no new data were created or analyzed in this study.
Corresponding author: Yuki Ishibashi, MD, Department of Orthopaedic Surgery, Japanese Red Cross Musashino Hospital, 1-26-1 Sakaiminatocho, Musashino 180-0023, Tokyo, Japan.
Received: November 14, 2025
Revised: December 19, 2025
Accepted: February 6, 2026
Published online: May 18, 2026
Processing time: 186 Days and 6.8 Hours
Revised: December 19, 2025
Accepted: February 6, 2026
Published online: May 18, 2026
Processing time: 186 Days and 6.8 Hours
Core Tip
Core Tip: This retrospective cohort study included 24 patients who underwent surgery for femoral metastasis by orthopedic doctors and received preoperative systemic therapy. We investigated the relationship between overall survival and clinical parameters, including serum biochemical concentrations and blood cell counts. Administering systemic treatment after surgery may be a favorable prognostic factor in patients undergoing surgery for femoral metastasis who have also received preoperative systemic treatment.